VICTORIA, Aug. 29 /CNW/ - CardioComm Solutions Inc. (TSX-V:CCG)
("CardioComm", the "Company"), is pleased to provide a Corporate update as
- CardioComm will launch GlobalCardio 12 Lead ECG web based system
commencing in September 2007. CardioComm's model is to provide a 12
lead ECG device to physicians along with access to GlobalCardio 12
Lead to allow physicians to provide ECGs for patients in clinic in an
effective low cost transaction based method. This system will
revolutionize basic cardiac care in physician's offices. The system
has been successfully trialed in four cardiology clinics for eight
months and two family practices for two months.
- CardioComm has been engaged by the Canadian Heart Research Centre to
provide ECG services in family physicians offices participating in
one of the largest outpatient atrial fibrillation studies in Canada.
This is further support for GlobalCardio 12 Lead system.
- CardioComm has secured a development contract for $250,000 related to
further 12 lead development
- CardioComm continues to streamline operations and refocusing business
development activities looking forward to the launch of GlobalCardio
- The financial statements and Management Discussion and Analysis for
the period ending June 30, 2007 have been filed today and are
available at www.sedar.com
About CardioComm Solutions Inc.
CardioComm's patented and proprietary technology is used in products for
the recording, viewing, analyzing and storing of electrocardiograms (ECGs),
for diagnosis and management of cardiac patients. The Company's products are
sold worldwide through a combination of its external distribution network and
its North American based sales team. CardioComm has achieved its technical
goals of improved access and communication through the development of a
real-time ECG viewer. CardioComm is the first company to provide a real-time
means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables
ECGs to be viewed and controlled live, by physicians, over a global virtual
healthcare network. This technology is marketed as Global ECG Management
System (GEMS(TM)) and GlobalCardio(TM). CardioComm's software products have
been cleared for sale in the United States by the U.S. Food and Drug
Administration. The Company has earned the latest ISO 13485 certification.
On behalf of the Board of Directors of CardioComm Solutions Inc.
Stephen R. Martin, President & CEO
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release
For further information:
For further information: For investor information, please contact:
Stephen Martin, 1-877-744-1122